Janssen Vaccines

From WikiMD's Wellness Encyclopedia

Janssen Vaccines is a division of Janssen Pharmaceuticals, which is itself a subsidiary of Johnson & Johnson. Janssen Vaccines is focused on the development, production, and marketing of vaccines to prevent and combat infectious diseases.

History[edit | edit source]

Janssen Vaccines was established as Crucell in 2000, following the merger of several biotechnology companies. In 2011, it was acquired by Johnson & Johnson and renamed as Janssen Vaccines.

Research and Development[edit | edit source]

Janssen Vaccines conducts extensive research and development in the field of vaccinology, with a particular focus on diseases such as HIV, Ebola, RSV, and Zika virus. The company's research strategy involves the use of innovative technologies, such as adenovirus-based vectors, to develop novel vaccines.

Products[edit | edit source]

One of the most notable products of Janssen Vaccines is the Janssen COVID-19 Vaccine, also known as Ad26.COV2.S. This vaccine was granted Emergency Use Authorization by the FDA in February 2021 for the prevention of COVID-19 in individuals 18 years of age and older.

See Also[edit | edit source]

References[edit | edit source]


Contributors: Prab R. Tumpati, MD